\nNanoVibronix, Inc., (NASDAQ: NAOV), a medical device company that produces the UroShield\u00ae, PainShield\u00ae and WoundShield\u00ae Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today announced that it has entered into securities purchase agreements with certain institutional and accredited investors to raise $6.0 million through the issuance of 8,571,429 shares of its common stock (or common stock equivalents) at a purchase price of $0.70 per share in a private placement. The closing of the private placement is expected to occur on or about December 4, 2020, subject to satisfaction of customary closing conditions.\n<\/p>\n
\nH.C. Wainwright & Co., LLC acted as the sole placement agent for the offering.\n<\/p>\n
\nThe Company intends to use the net proceeds for general corporate purposes.\n<\/p>\n
\nThe offer and sale of the foregoing securities are being made in a transaction not involving a public offering and have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), or applicable state securities laws. Accordingly, the securities may not be reoffered or resold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws.\n<\/p>\n
\nUnder an agreement with the investors, the Company is required to file an initial registration statement with the Securities and Exchange Commission covering the resale of the shares of common stock to be issued to the investors no later than 10 days after today and to use best efforts to have the registration statement declared effective as promptly as practical thereafter, and in any event no later than 90 days after today in the event of a \u201cfull review\u201d by the Securities and Exchange Commission.\n<\/p>\n
\nThis press release does not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of the securities in any state in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state.\n<\/p>\n
About NanoVibronix, Inc.<\/b><\/p>\n
\nNanoVibronix, Inc. (NASDAQ: NAOV) is a medical device company headquartered in Elmsford, New York, with research and development in Nesher, Israel, focused on developing medical devices utilizing its patented low intensity surface acoustic wave (SAW) technology. The proprietary technology allows for the creation of low-frequency ultrasound waves that can be utilized for a variety of medical applications, including for disruption of biofilms and bacterial colonization, as well as for pain relief. The devices can be administered at home without the assistance of medical professionals. The Company\u2019s primary products include PainShield\u00ae, UroShield\u00ae and WoundShield\u00ae, all of which are portable devices suitable for administration at home without assistance of medical professionals. Additional information about NanoVibronix is available at: www.nanovibronix.com<\/a>.\n<\/p>\n Forward-looking Statements<\/b><\/p>\n \nThis press release contains \u201cforward-looking statements.\u201d Such statements may be preceded by the words \u201cintends,\u201d \u201cmay,\u201d \u201cwill,\u201d \u201cplans,\u201d \u201cexpects,\u201d \u201canticipates,\u201d \u201cprojects,\u201d \u201cpredicts,\u201d \u201cestimates,\u201d \u201caims,\u201d \u201cbelieves,\u201d \u201chopes,\u201d \u201cpotential\u201d or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company\u2019s control, and cannot be predicted or quantified, and include, among others, statements regarding the completion of the private placement, the satisfaction of customary closing conditions related to the private placement and the intended use of net proceeds from the private placement; consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with: (i) the geographic, social and economic impact of COVID-19 on the Company\u2019s ability to conduct its business and raise capital in the future when needed, (ii) market acceptance of our existing and new products or lengthy product delays in key markets; (iii) negative or unreliable clinical trial results; (iv) inability to secure regulatory approvals for the sale of our products; (v) intense competition in the medical device industry from much larger, multinational companies,; (vi) product liability claims; (vii) product malfunctions; (viii) our limited manufacturing capabilities and reliance on subcontractor assistance; (ix) insufficient or inadequate reimbursements by governmental and\/or other third party payers for our products; (x) our ability to successfully obtain and maintain intellectual property protection covering our products; (xi) legislative or regulatory reform impacting the healthcare system in the U.S. or in foreign jurisdictions; (xii) our reliance on single suppliers for certain product components, (xiii) the need to raise additional capital to meet our future business requirements and obligations, given the fact that such capital may not be available, or may be costly, dilutive or difficult to obtain; (xiv) our conducting business in foreign jurisdictions exposing us to additional challenges, such as, e.g., foreign currency exchange rate fluctuations, logistical and communications challenges, the burden and cost of compliance with foreign laws, and political and\/or economic instabilities in specific jurisdictions; (xv) the timing, size and completion of the private placement; and (xvi) market and other conditions. More detailed information about the Company and the risk factors that may affect the realization of forward looking statements is set forth in the Company\u2019s filings with the Securities and Exchange Commission (SEC), including the Company\u2019s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC\u2019s web site at: http:\/\/www.sec.gov<\/a>. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events, or otherwise, except as required by law.\n<\/p>\n View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20201202005843\/en\/<\/a><\/span><\/p>\n Investor Contacts: KEYWORDS:<\/b> United States North America New York<\/p>\n INDUSTRY KEYWORDS:<\/b> Professional Services Entertainment Medical Devices Health Other Professional Services Film & Motion Pictures<\/p>\n MEDIA:<\/b><\/p>\n NanoVibronix Announces $6.0 Million Private Placement ELMSFORD, N.Y.–(BUSINESS WIRE)– NanoVibronix, Inc., (NASDAQ: NAOV), a medical device company that produces the UroShield\u00ae, PainShield\u00ae and WoundShield\u00ae Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today announced that it has entered into securities purchase agreements with certain institutional and accredited investors to raise $6.0 million through the issuance of 8,571,429 shares of its common stock (or common stock equivalents) at a purchase price of $0.70 per share in a private placement. The closing of the private placement is expected to occur on or about December 4, 2020, subject to satisfaction of customary closing conditions. H.C. Wainwright & Co., LLC acted as the sole placement agent for the offering. The Company intends to use … <\/p>\n<\/p>\n
\n<\/b>
NanoVibronix, Inc.
\n
bmurphy@nanovibronix.com
\n<\/a>
(630) 338-5022
\n
Or:
\n
Brett Maas, Managing Principal, Hayden IR, LLC
\n
brett@haydenir.com
\n<\/a>
(646) 536-7331\n<\/p>\n\n","protected":false},"excerpt":{"rendered":"